哈尔滨誉衡药业股份有限公司 2023 年度以简易程序向特定对象发行股票 证券代码：002437 证券简称：誉衡药业 公告编号：2023-062 方案论证分析报告 二〇二三年八月 哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司（以下简称"誉衡药业"或"公司"）召开第 六届董事会第七次会议审议通过了公司以简易程序向特定对象发行股票的相关 议案。根据《上市公司证券发行注册管理办法》等相关规定，公司董事会编制了 本次以简易程序向特定对象发行股票方案论证分析报告。 为满足公司业务发展的资金需求，根据《中华人民共和国公司法》、《中华人 民共和国证券法》和《上市公司证券发行注册管理办法》等有关法律、法规和规 范性文件和《公司章程》的规定，公司拟实施 2023 年度以简易程序向特定对象 发行股票计划（以下简称"本次发行"），本次拟发行的股票数量不超过 20,000.00 万股（含本数），募集资金不超过 30,000.00 万元（含本数），扣除发行费用后的 募集资金净额用于药物研发项目、营销信息服务平台系统建设项目以及偿还银行 借款项目。 本报告中如无特别说明，相关用语具有与《哈尔滨誉衡药业股份有限公司 2023 年度 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2023-058 哈尔滨誉衡药业股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 8 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）以短信 及电子邮件的方式向全体董事发出了《关于召开公司第六届董事会第七次会议的 通知》及相关议案。 2023 年 8 月 11 日，第六届董事会第七次会议以现场结合通讯方式召开。本 次会议应参加董事 9 人，实际参加董事 9 人。胡晋先生、国磊峰先生、刁秀强先 生、纪作哲先生 4 人现场出席会议，王东绪先生、周康先生、潘敏女士、姜明辉 女士、张晓丹先生 5 人以通讯表决方式出席会议。 会议的召集、召开及表决程序符合《公司法》、《公司章程》及《董事会议 事规则》等有关规定。会议由董事长胡晋先生主持，经与会董事认真审议及表决 形成如下决议： 一、审议通过了《关于公司符合以简易程序向特定对象发行股票条件的议案》 根据《公司法》、《证券法》、《上市公司证券发行注册管理办法》等法律、 法规和 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2023-066 哈尔滨誉衡药业股份有限公司 关于最近五年不存在被证券监管部门和交易所 董 事 会 二〇二三年八月十二日 第 1 页 哈尔滨誉衡药业股份有限公司（以下简称"公司"）自上市以来，严格按照 《公司法》、《证券法》、《深圳证券交易所股票上市规则》以及《公司章程》的有 关规定和要求规范运作，致力于完善公司治理结构，建立健全内部控制制度，提 高公司规范运作水平，积极保护投资者合法权益，促进公司持续健康发展。 根据相关法律法规要求，公司对最近五年是否被证券监管部门和深圳证券交 易所采取监管措施或者处罚情况进行了自查，经自查： 最近五年内公司不存在被中国证券监督管理委员会及其派出机构和深圳证 券交易所采取监管措施或处罚的情况，不涉及整改落实事项。 特此公告。 哈尔滨誉衡药业股份有限公司 采取监管措施或处罚情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

一、审议通过了《关于公司符合以简易程序向特定对象发行股票条件的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等法律、法规和规范性文件及《公司章程》的有关规定，经 认真对照上市公司以简易程序向特定对象发行股票的要求，并对公司实际情况进 行逐项自查论证后，监事会认为公司符合现行相关法律、法规及规范性文件中关 于上市公司以简易程序向特定对象发行股票的各项条件。 公司于 2023 年 5 月 15 日召开的 2022 年年度股东大会已审议通过了《关于 提请 2022 年年度股东大会授权董事会办理小额快速融资相关事宜的议案》，因 此，本议案及其他相关议案无需提交公司股东大会审议。 哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2023-060 哈尔滨誉衡药业股份有限公司 第六届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 8 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）以短信 及电子邮件的方式向全体监事发出了《关于召开公司第六届监事 ...

证券代码：002437 证券简称：誉衡药业 公告编号：2023-063 哈尔滨誉衡药业股份有限公司 2023 年度以简易程序向特定对象发行股票 募集资金使用的可行性分析报告 二〇二三年八月 一、本次募集资金的使用计划 公司本次发行股票募集资金总额不超过3亿元（含本数），且不超过公 司最近一年末净资产的20%。募集资金在扣除相关发行费用后的净额拟投 入如下项目： 在上述募集资金投资项目的范围内，公司可根据项目的进度、资金需求等实 际情况，对相应募集资金投资项目的投入顺序和具体金额进行适当调整。本次发 行的募集资金到位前，公司可以根据募集资金投资项目的实际情况，以自筹资金 先行投入，并在募集资金到位后予以置换。 本次以简易程序向特定对象发行股票的募集资金到位后，如实际募集资金净 额少于上述拟投入募集资金金额，募集资金不足部分由公司以自有资金或通过其 他融资方式解决。公司将根据募集资金专户存储制度，将募集资金存放于专项账 户集中管理，专款专用。 本次募集资金使用中，资本性支出和费用化支出情况如下： 如上表所示，本次募集资金投资中，费用化支出的金额为 9,000.00 万元， 占募集资金投资总额的比例为 30.00% ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the same period last year[21]. - The company's operating revenue for the current reporting period is ¥1,432,663,200.48, representing a decrease of 10.43% compared to ¥1,599,568,666.45 in the same period last year[27]. - The net profit attributable to shareholders of the listed company is ¥28,249,027.25, an increase of 5.13% from ¥26,870,523.13 in the previous year[27]. - The company reported a total comprehensive income of CNY 33,923,280.05 for the first half of 2023, compared to CNY 34,582,142.11 in the same period of 2022[145]. - The total operating revenue for the first half of 2023 was CNY 1,432,663,200.48, a decrease of 10.5% compared to CNY 1,599,568,666.45 in the same period of 2022[143]. - The company reported a total of ¥1,475,330.54 in non-recurring gains and losses for the current period[32]. - The total profit loss for the first half of 2023 was CNY -75,947,894.12, compared to a loss of CNY -59,618,771.34 in the first half of 2022, indicating a worsening financial performance[148]. Research and Development - The company plans to invest RMB 300 million in R&D for new drug development in the next fiscal year[21]. - The company has 9 products in the R&D phase that have reached the pilot test stage, indicating ongoing innovation efforts[38]. - Research and development expenses were ¥38,367,527.40, down 4.58% from ¥40,207,918.39 in the previous year[44]. - The company has allocated 370 million yuan for research and development, which is 18% of total revenue, to enhance its product offerings[158]. - R&D expenses for the first half of 2023 amounted to CNY 1,380,438.73, a decrease from CNY 3,200,000.00 in the same period of 2022, reflecting a significant reduction in investment[147]. Market Expansion - User data indicates a 20% increase in the number of active customers, reaching 1.5 million by the end of June 2023[21]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 25%[21]. - The management has set a revenue target of RMB 2.5 billion for the full year 2023, reflecting a growth rate of 12%[21]. - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[158]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by strategic market expansion initiatives[158]. Financial Position - Total assets at the end of the reporting period amount to ¥3,617,614,586.47, a decrease of 11.21% from ¥4,074,185,955.01 at the end of the previous year[27]. - The company's equity attributable to shareholders increased to CNY 1,661,153,081.44 from CNY 1,631,237,579.41, showing a growth of approximately 1.8%[138]. - The total liabilities decreased to CNY 1,891,572,464.76 from CNY 2,370,644,737.61, a reduction of about 20.2%[138]. - The total liabilities to total assets ratio improved to approximately 52.2% from 58.1%[138]. - The company reported a total equity of 2,198 million yuan at the end of the reporting period[162]. Environmental Compliance - The company strictly adheres to environmental protection laws and has obtained the necessary pollution discharge permits[82]. - The company reported a total wastewater discharge of 36.5 tons per year, with COD emissions at 19.18 tons per year, and ammonia nitrogen emissions at 3.65 tons per year[83]. - The company has implemented strict adherence to environmental protection laws and regulations, ensuring that all pollution discharge standards are met[85]. - The company has upgraded and modified environmental protection equipment to ensure normal operation of treatment facilities[85]. - There were no administrative penalties due to environmental issues during the reporting period[86]. Corporate Governance - The company has not engaged in any securities or derivative investments during the reporting period[59][60]. - The company has not experienced any major litigation or arbitration matters during the reporting period[94]. - The company has not conducted any poverty alleviation or rural revitalization initiatives during the reporting period[86]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[79]. - The company has no controlling shareholder as of April 4, 2023, following a change in control[126]. Related Party Transactions - The company reported a significant related party transaction amounting to ¥825.2 million, representing 0.58% of the approved transaction limit[97]. - The total amount of related party transactions in the past twelve months reached ¥3,400 million[97]. - The company sold 100% equity of its subsidiary to a related party for a transfer price of 58.24 million yuan, with the net asset value at 80.24 million yuan, resulting in no significant impact on financial performance[99]. - The company has established a sales agreement with Guizhou Province Medical Procurement, with a transaction amount of ¥2,500 million[97]. - The company approved a related party transaction limit of 9 million yuan for the sale of products by its subsidiary, which was executed with a transaction amount of 564,700 yuan in January-February 2023[98].

Group 1: Company Performance and Financial Impact - The company has confirmed an investment loss of 35.74 million yuan from January to May 2023, with an estimated total impact on net profit for the year ranging from -8,000 to -9,000 million yuan [1] - The domestic biopharmaceutical industry is facing intensified competition, with several PD-1/PD-L1 related products approved for market, diminishing the competitive edge of the company's product [1] - The company plans to divest its entire stake in its subsidiary, Yuheng Biotech, due to significant losses affecting overall performance [1] Group 2: Research and Development Projects - Current research projects focus on orthopedic, cardiovascular, and vitamin/mineral fields, utilizing self-research, CRO partnerships, and collaborative development [2] - The company maintains a strong market position with its injectable compound vitamins, holding over 80% market share, and potassium chloride sustained-release tablets, which have increased market share to over 30% [2] Group 3: Production Capacity and Utilization - As of the end of 2022, the company operates 50 production lines with an annual capacity of 680 million injectable units and 2.65 billion oral solid units [3] - Utilization rates vary significantly across production lines, with potassium chloride sustained-release tablets exceeding 90% utilization, while some lines remain underutilized [3] Group 4: Market Strategy and Sales - The company aims to stabilize its existing business and explore first-generic drugs and new differentiated products in the short term, avoiding further investments in the biopharmaceutical sector for now [1] - The impact of centralized procurement policies on the company's main products is positive, particularly for potassium chloride sustained-release tablets, with no significant changes in overall revenue expected this year [3]

| | □特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | 类别 | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 2023 5 15 (周一) 下午 14:00~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、副总经理、董事会秘书刘月寅 | | 员姓名 | 2、董事、副总经理、财务总监纪作哲 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、胡晋你好，你是誉衡董事长也是信邦制药董事，可以客 | | | 观评价一下两公司经营状况，市值管理和高管们的薪酬情况，深 | | | 交所的问询你们的理由也很充分，但作为对比是不是没可比性， | | | 你们高管对公司发展是否有信心，如有，是否可以用你们来之不 | ...

Group 1: Event Details - The event will be held online on May 15, 2023, from 14:00 to 16:30 [1] - Investors can participate via the "Panjing Roadshow" website, WeChat, or the Panjing Roadshow APP [1] Group 2: Company Engagement - Company executives will discuss the 2022 annual performance, corporate governance, development strategy, operational status, financing plans, and sustainable development [1] - The company encourages active participation from investors [1] Group 3: Assurance of Information - The company and its board guarantee that the disclosed information is true, accurate, and complete, with no false records or misleading statements [1]

Financial Performance - The company's revenue for Q1 2023 was ¥681,168,970.96, a decrease of 12.02% compared to ¥774,211,987.48 in the same period last year[4] - Net profit attributable to shareholders reached ¥20,058,598.74, representing a significant increase of 1,909.35% from ¥998,263.43 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0091, an increase of 1,720.00% compared to ¥0.0005 in the same period last year[4] - The total operating revenue for the current period is ¥681,168,970.96, a decrease of 11.99% compared to ¥774,211,987.48 in the previous period[20] - The net profit for the current period is ¥21,870,444.70, significantly higher than ¥3,046,070.09 in the previous period, marking a growth of 619.06%[21] - The total comprehensive income for the current period is ¥21,156,409.21, compared to ¥2,822,278.80 in the previous period, showing a substantial increase[21] Cash Flow - The net cash flow from operating activities was ¥83,699,367.15, up 47.30% from ¥56,821,196.52 in the previous year[4] - The net cash flow from operating activities was ¥83,699,367.15, an increase from ¥56,821,196.52 in the previous period, indicating a positive trend in operational cash generation[24] - The net cash flow from investing activities was ¥25,147,232.08, a turnaround from a negative cash flow of ¥117,006,134.10 in the previous year[9] - The net cash flow from financing activities was -¥101,258,939.96, compared to -¥27,724,573.13 in the previous period, showing increased cash outflows related to financing[25] - The total cash inflow from investment activities was ¥57,198,472.28, significantly lower than ¥314,461,007.58 in the previous period, reflecting a decrease in investment returns[24] - The net increase in cash and cash equivalents was ¥6,815,714.09, contrasting with a decrease of ¥88,440,630.07 in the previous period, suggesting improved liquidity management[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,948,401,721.10, a decrease of 3.09% from ¥4,074,185,955.01 at the end of the previous year[4] - The total liabilities amount to ¥2,235,154,094.49, a decrease from ¥2,370,644,737.61 in the previous period[18] - The total current assets are reported at 1,738,338,700.12 RMB, a decrease from 1,816,197,553.88 RMB, indicating a decline of about 4.3%[16] - The total non-current assets amount to 2,210,063,020.98 RMB, down from 2,257,988,401.13 RMB, representing a decrease of approximately 2.1%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 93,421[11] - Harbin Yuheng Group Co., Ltd. holds 32.13% of shares, totaling 706,248,522 shares, which are frozen[11] - The top ten shareholders include YU HENG INTERNATIONAL INVESTMENTS CORPORATION with 2.58% and ORIENTAL KEYSTONE INVESTMENT LIMITED with 1.95%[11][12] - The company has no controlling shareholder or actual controller as of the report date, following the bankruptcy of Harbin Yuheng Group[13] - The company’s stock held by Harbin Yuheng Group has been completely auctioned and transferred, with no remaining shares held by the group[13] Operational Efficiency - The total operating costs for the current period are ¥636,373,987.48, down 13.27% from ¥733,867,370.83 in the previous period[20] - Research and development expenses for the current period are ¥13,997,253.96, down from ¥19,378,770.25 in the previous period, indicating a reduction of 27.56%[20] - Cash paid for purchasing goods and services was ¥98,639,590.05, compared to ¥161,161,410.50 in the previous period, reflecting a decrease in operational expenditures[24] - Cash paid for employee compensation was ¥115,102,392.56, down from ¥160,976,169.26, indicating cost control measures[24] Investment Performance - The company reported an investment loss of ¥20,774,804.75, compared to a loss of ¥10,283,242.28 in the previous period, representing an increase in losses[20] - Investment income showed a significant decline of 102.03%, with losses from equity method investments increasing[9] - The company reported cash received from investment recoveries of ¥56,383,625.67, a significant drop from ¥300,150,000.00 in the previous period[24] Legal Matters - The company has ongoing litigation related to a contract dispute, with a total of 1,524.40 million RMB received and 140.09 million RMB still owed[14] Management and Control - The company’s management team remains stable, and its independent operational capability is not affected by the change in control[13]